全球放射性药物可及性与供应问题:核医学全球倡议项目
核医学全球倡议组织于2012年由13个国际组织成立,其第二个项目通过调查35个国家的可用放射性同位素、放射性药物及试剂盒,评估全球放射性药物可及性与供应问题。结果突出显示单一供应商依赖、监管与报销问题以及设施和人力问题,尤其在中低收入国家。结论提出解决策略以确保及时公平的患者可及性,并强调新冠疫情下供应链中断后确保可靠供应的优先性。
要点
- 调查覆盖35个国家,揭示放射性药物可及性受单一供应商、监管和报销问题影响。
- 中低收入国家面临更突出的设施和人力问题,影响放射性药物可及性。
- 提出策略以解决可及性问题,并强调新冠疫情下确保可靠供应的全球优先性。
核心结论
- 核医学全球倡议项目提出策略以解决放射性药物可及性与供应问题,确保全球患者及时公平获得核医学诊疗。
- 新冠疫情导致全球供应链中断后,确保放射性药物可靠供应成为全球核医学实践的优先事项。
研究设计与样本
- 核医学全球倡议由13个国际组织于2012年成立,第二个项目通过调查问卷收集35个国家的信息。
- 调查内容包括可用放射性同位素、诊断和治疗用放射性药物及试剂盒,以及影响可及性的问题。
主要发现
- 调查评估了各国使用的放射性药物及其供应来源的详细信息。
- 答复突出显示可及性问题,特别归因于单一供应商依赖、监管问题和报销问题。
- 设施和人力问题也被强调,尤其在中低收入国家。
临床怎么用
- 核医学实践应关注放射性药物供应来源的多样性,减少对单一供应商的依赖。
- 需应对监管和报销障碍,并加强中低收入国家的设施和人力建设以改善可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the practice and application of nuclear medicine. The first project focused on standardization of administered activities in pediatric nuclear medicine and resulted in 2 articles. For its second project the Nuclear Medicine Global Initiative chose to explore issues impacting on access and availability of radiopharmaceuticals around the world. Methods: Information was obtained by survey responses from 35 countries on available radioisotopes, radiopharmaceuticals, and kits for diagnostic and therapeutic use. Issues impacting on access and availability of radiopharmaceuticals in individual countries were also identified. Results: Detailed information on radiopharmaceuticals used in each country, and sources of supply, was evaluated. Responses highlighted problems in access, particularly due to the reliance on a sole provider, regulatory issues, and reimbursement, as well as issues of facilities and workforce, particularly in low- and middle-income countries. Conclusion: Strategies to address access and availability of radiopharmaceuticals are outlined, to enable timely and equitable patient access to nuclear medicine procedures worldwide. In the face of disruptions to global supply chains by the coronavirus disease 2019 outbreak, renewed focus on ensuring a reliable supply of radiopharmaceuticals is a major priority for nuclear medicine practice globally.
引用
- Cutler CS, Bailey E, Kumar V, et al. Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. J Nucl Med. 2020. PMID: 32646881. doi:10.2967/jnumed.120.247197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。